Atopic Keratoconjunctivitis (AKC) Market Expected to Witness Steady Growth Through 2036, Supported by Rising Disease Awareness and Emerging Targeted Therapies | DelveInsight

The Atopic Keratoconjunctivitis (AKC) market is anticipated to witness notable growth across the Seven Major Markets (7MM) during the forecast period (2026-2036). Market expansion is expected to be driven by the increasing diagnosed patient population, growing awareness among ophthalmologists and dermatologists, improved recognition of severe ocular allergic diseases, and the anticipated introduction of targeted therapies designed to address chronic ocular inflammation. Although AKC remains a relatively uncommon disease, its vision-threatening complications and significant unmet medical needs continue to create opportunities for therapeutic innovation.

DelveInsight's "Atopic Keratoconjunctivitis (AKC) Market Insights, Epidemiology, and Market Forecast-2036" report provides a comprehensive assessment of disease epidemiology, current treatment practices, emerging therapies, market trends, pricing analysis, therapy uptake, reimbursement landscape, and market forecasts across the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan. The report further evaluates patient burden, competitive intelligence, key opinion leader perspectives, and commercial opportunities expected to shape the AKC market through 2036.

The report also delivers detailed insights into historical and forecasted market performance, epidemiological trends, treatment algorithms, unmet needs, SWOT analysis, pricing dynamics, and the evolving competitive landscape to support strategic decision-making for stakeholders operating in the ophthalmology and immunology sectors.

To know more about the Atopic Keratoconjunctivitis (AKC) market, epidemiology, and forecast, Click here:
https://www.delveinsight.com/sample-request/atopic-keratoconjunctivitis-market?utmsource=openpr&utm_medium=pressrelease&utm_campaign=kspr

Key Takeaways from the Atopic Keratoconjunctivitis (AKC) Market Report

• The Atopic Keratoconjunctivitis (AKC) market is expected to expand steadily across the 7MM during the forecast period (2026-2036), supported by increasing disease recognition, improved diagnosis, greater awareness among eye care specialists, and the anticipated launch of targeted therapies for severe and refractory disease.
• AKC is a chronic inflammatory disease affecting the conjunctiva and cornea, commonly associated with atopic dermatitis, and has the potential to cause serious ocular complications including corneal scarring, keratopathy, thinning, and permanent vision loss if inadequately treated.
• Despite its potentially blinding nature, there are currently no FDA-approved therapies specifically indicated for ocular AKC, and treatment largely depends on off-label use of topical corticosteroids, antihistamines, mast cell stabilizers, and calcineurin inhibitors.
• According to the report, 25-40% of patients with atopic dermatitis develop AKC, while more than 95% of AKC patients have eczema and 87% have a history of asthma, highlighting the strong association between ocular allergy and systemic atopic disease.
• AKC symptoms typically begin during the late teens or early twenties and often persist through the fourth or fifth decade of life, contributing to a substantial long-term disease burden.
• The emerging clinical pipeline remains limited; however, DFL24498 (Isocyclosporin) developed by Dompé Farmaceutici S.p.A. has advanced into Phase III clinical development, representing one of the most promising investigational therapies for AKC.

Key Factors Driving the Atopic Keratoconjunctivitis (AKC) Market
Increasing Recognition of Severe Ocular Allergic Diseases

Improved awareness of chronic ocular allergy among ophthalmologists and dermatologists is leading to earlier diagnosis and better disease management. Growing recognition of AKC as a potentially vision-threatening disease is expected to increase treatment rates and expand market opportunities.

Growing Burden of Atopic Disorders
The increasing prevalence of atopic dermatitis, asthma, and other allergic disorders continues to expand the population at risk for AKC. Since AKC frequently develops in patients with systemic atopic disease, rising rates of allergic conditions are expected to support long-term market growth.

Advancements in Targeted Immunomodulatory Therapies

The development of novel immunomodulatory therapies capable of reducing chronic ocular inflammation while minimizing corticosteroid exposure is expected to transform AKC management. Emerging therapies designed to improve ocular bioavailability and provide sustained anti-inflammatory activity represent important advances for patients requiring long-term treatment.

Significant Unmet Clinical Need
Current therapies primarily provide symptomatic relief but fail to adequately address the chronic immunopathology of AKC. Long-term corticosteroid use is associated with complications such as glaucoma, cataracts, and ocular infections, underscoring the need for effective steroid-sparing therapies and innovative drug delivery technologies.

Atopic Keratoconjunctivitis (AKC) Market Analysis

• Atopic Keratoconjunctivitis remains a relatively rare but potentially blinding chronic ocular inflammatory disease characterized by persistent allergic inflammation affecting both the conjunctiva and cornea. Disease management currently relies on environmental control, topical antihistamines, mast cell stabilizers, corticosteroids, and calcineurin inhibitors. However, prolonged dependence on corticosteroids presents considerable safety concerns, creating demand for therapies capable of providing durable disease control with improved long-term safety.
• The therapeutic pipeline remains limited compared with other allergic diseases, highlighting a substantial commercial opportunity for companies developing mechanism-based ocular immunotherapies. DFL24498 (Isocyclosporin), currently undergoing Phase III clinical evaluation, has demonstrated encouraging clinical results and has the potential to become one of the first therapies specifically developed for AKC. Additional early-stage candidates such as NTX-2010 further illustrate growing industry interest in addressing this underserved indication.
• According to DelveInsight, continued improvements in disease recognition, increasing awareness of ocular allergic disorders, expansion of the diagnosed patient pool, advances in targeted immunomodulation, and the anticipated commercialization of emerging therapies are expected to support steady growth of the AKC market across the 7MM through 2036. As innovation continues, next-generation therapies may significantly improve long-term disease control while reducing the treatment burden associated with chronic corticosteroid use.

Get a Free sample for the Atopic Keratoconjunctivitis (AKC) Market Forecast, Size & Share Analysis Report:
https://www.delveinsight.com/sample-request/atopic-keratoconjunctivitis-market?utmsource=openpr&utm_medium=pressrelease&utm_campaign=kspr

Atopic Keratoconjunctivitis (AKC) Competitive Landscape

• The Atopic Keratoconjunctivitis (AKC) therapeutic landscape remains highly underserved, with no FDA-approved therapies specifically indicated for AKC despite the disease's chronic inflammatory nature and potential to cause irreversible vision impairment. Current management primarily relies on off-label therapies, including topical antihistamines, mast cell stabilizers, corticosteroids, and calcineurin inhibitors such as cyclosporine and tacrolimus. While these agents help control symptoms and inflammation, long-term corticosteroid use is associated with significant ocular complications, creating a strong demand for safer, targeted therapies.
• Compared with other allergic and atopic diseases, the AKC pipeline remains relatively limited. However, increasing understanding of ocular immunopathology has encouraged the development of mechanism-based therapies designed to provide sustained disease control while reducing steroid dependence. Among emerging candidates, DFL24498 (Isocyclosporin) from Dompé Farmaceutici S.p.A. currently represents the most advanced clinical program, while additional preclinical assets are expected to strengthen the future treatment landscape.

Emerging Therapies Driving the Atopic Keratoconjunctivitis (AKC) Market

DFL24498 (Isocyclosporin): Dompé Farmaceutici S.p.A.
DFL24498 (Isocyclosporin) is an investigational therapy being developed by Dompé Farmaceutici S.p.A. for the treatment of Atopic Keratoconjunctivitis. The molecule acts as a dual inhibitor of transient receptor potential mucolipin-2 (TRPML2) and calcineurin, both of which regulate immune and inflammatory responses involved in chronic inflammatory eye diseases. The therapy has been specifically designed to improve ocular solubility, bioavailability, tissue distribution, and tolerability while reducing the need for prolonged corticosteroid therapy.
DFL24498 is currently undergoing a Phase III clinical trial, scheduled to continue through 2027. In December 2025, Dompé announced the dosing of the first patient in the Phase III study across Europe and the United States. Earlier, the pivotal Phase II ISAAK study demonstrated statistically significant improvements in AKC-associated signs and symptoms after four weeks of treatment compared with vehicle control, while also showing favorable tolerability with no discontinuations related to treatment.

NTX-2010: NexEos Bio
NTX-2010, developed by NexEos Bio, is currently in the preclinical stage for the treatment of Atopic Keratoconjunctivitis. Research is focused on evaluating the molecule's mechanism of action, pharmacokinetic characteristics, safety profile, and anti-inflammatory activity in experimental models of allergic ocular disease. If clinical development is successful, NTX-2010 may provide a targeted therapeutic option capable of addressing the substantial unmet need for long-term disease control beyond corticosteroids and off-label immunomodulators.

Recent Developments in the Atopic Keratoconjunctivitis (AKC) Market

• In December 2025, Dompé Farmaceutici S.p.A. announced the dosing of the first patient in the Phase III clinical study evaluating DFL24498 (Isocyclosporin) across Europe and the United States.
• The company's earlier Phase II ISAAK trial demonstrated statistically significant improvements in both the signs and symptoms of AKC after four weeks of treatment compared with vehicle control, while reporting favorable safety and tolerability.
• DFL24498 (Isocyclosporin) is expected to remain in Phase III development through 2027, representing one of the most advanced investigational therapies for AKC.
• NTX-2010, developed by NexEos Bio, continues preclinical development as a potential targeted therapy for chronic ocular inflammation associated with AKC.

What is Atopic Keratoconjunctivitis (AKC)?

Atopic Keratoconjunctivitis (AKC) is a chronic inflammatory disease affecting the conjunctiva, cornea, and eyelids, most commonly associated with atopic dermatitis. Unlike seasonal allergic conjunctivitis, AKC is persistent and progressive, with inflammation capable of causing severe ocular complications including keratopathy, conjunctival scarring, corneal thinning, corneal ulceration, and permanent vision loss if left inadequately treated. The disease is characterized by both Type I and Type IV hypersensitivity reactions, involving mast cells, eosinophils, and chronic immune-mediated inflammation of the ocular surface.

Current treatment focuses on reducing ocular inflammation, relieving symptoms, minimizing disease exacerbations, and preventing long-term complications. Management typically includes allergen avoidance, topical antihistamines, mast cell stabilizers, short-term corticosteroids, and steroid-sparing immunomodulators such as cyclosporine and tacrolimus. Because prolonged corticosteroid therapy increases the risk of glaucoma, cataracts, and ocular infections, the development of targeted therapies with improved long-term safety remains a major clinical priority.

Atopic Keratoconjunctivitis (AKC) Epidemiology Segmentation

The DelveInsight report provides a detailed epidemiological assessment of Atopic Keratoconjunctivitis across the Seven Major Markets (7MM) during 2022-2036, segmented into:
• Total Prevalent Cases of AKC
• Diagnosed Prevalent Cases of AKC
• Age-specific Diagnosed Prevalent Cases
• Gender-specific Diagnosed Prevalent Cases
• Cause-specific Diagnosed Prevalent Cases
• Total Treatable Cases
• Country-specific epidemiology across the United States, Germany, France, Italy, Spain, the United Kingdom, and Japan.

Download the report to explore detailed epidemiology trends, emerging therapies, competitive intelligence, and commercial opportunities in the Atopic Keratoconjunctivitis (AKC) market:
https://www.delveinsight.com/sample-request/atopic-keratoconjunctivitis-market?utmsource=openpr&utm_medium=pressrelease&utm_campaign=kspr

Scope of the Atopic Keratoconjunctivitis (AKC) Market Report

• Study Period: 2022-2036
• Coverage: Seven Major Markets (7MM) - United States, Germany, France, Italy, Spain, the United Kingdom, and Japan.
• Key Companies: Dompé Farmaceutici S.p.A., NexEos Bio, and other companies developing novel therapies for Atopic Keratoconjunctivitis.
• Current Treatment Landscape: Off-label therapies including topical antihistamines, mast cell stabilizers, topical corticosteroids, calcineurin inhibitors (cyclosporine and tacrolimus), and supportive care.
• Emerging Therapies: DFL24498 (Isocyclosporin), NTX-2010, and additional investigational therapies under development.
• Epidemiology Segmentation: Total prevalent cases, diagnosed prevalent cases, age-specific, gender-specific, cause-specific diagnosed prevalent cases, and total treatable cases across the 7MM.
• Market Insights: Historical and forecasted market size, therapy uptake, pricing trends, analogue assessment, competitive landscape, unmet needs, SWOT analysis, and market forecasts through 2036.
• Market Access: Country-specific reimbursement and Health Technology Assessment (HTA) landscape across the United States, Germany, France, Italy, Spain, the United Kingdom, and Japan.
• Additional Coverage: Patient journey, Key Opinion Leader (KOL) perspectives, therapy launch assessment, reimbursement dynamics, market access strategies, and analyst views.

To learn more about the Atopic Keratoconjunctivitis (AKC) market, epidemiology, and emerging treatment landscape, visit:
https://www.delveinsight.com/sample-request/atopic-keratoconjunctivitis-market?utmsource=openpr&utm_medium=pressrelease&utm_campaign=kspr

Table of Contents

• Atopic Keratoconjunctivitis (AKC) Market Report Introduction
• Atopic Keratoconjunctivitis (AKC) Market Executive Summary
• Atopic Keratoconjunctivitis (AKC) Market Overview
• Atopic Keratoconjunctivitis (AKC) Epidemiology Analysis
• Patient Journey
• Current Treatment Landscape
• Emerging Therapies
• Atopic Keratoconjunctivitis (AKC) Market Dynamics
• Atopic Keratoconjunctivitis (AKC) Market Size and Forecast (2022-2036)
• Competitive Landscape
• Key Companies
• Key Emerging Therapies
• Epidemiology Segmentation
• Pricing Trends and Analogue Analysis
• Market Access and Reimbursement
• Key Opinion Leaders' Views
• Unmet Needs
• SWOT Analysis
• Market Drivers and Barriers
• Future Perspectives
• Analyst Views
• Appendix

Media Contact
Company Name: DelveInsight
Contact Person: Kirti Sharma
Email: info@delveinsight.com
Phone: +14699457679
Address: 304 S. Jones Blvd #2432
City: Albany
State: New York

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

This release was published on openPR.